What Is The Current and Historic Market Size Analysis Of The Biliary Tract Cancer Market?
The biliary tract cancer market has seen considerable growth due to a variety of factors.
• Recently, the biliary tract cancer market has been showing robust growth. The market size is set to expand from $0.67 billion in 2024 to $0.72 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%.
This growth seen in the recent past is a result of several factors including a rising number of biliary tract cancer cases, increasing needs for efficient treatment methods, heightened risk factors such as obesity, a growing elderly population, and more investments being funneled into research and development.
What are the Market Size and Expected Growth Rates for the Biliary Tract Cancer Market in the Coming Years?
The biliary tract cancer market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the biliary tract cancer market is anticipated to witness robust growth in the upcoming years, expanding to $0.95 billion by 2029 with a compound annual growth rate (CAGR) of 7.3%.
The projected growth within this period can be linked to changes in lifestyle, increased awareness, initiatives towards early detection, advantageous reimbursement policies, and expanding governmental policies. The forecast period is expected to see major trends such as advances in diagnostic and treatment technology, the use of immunotherapy, increasing demand for precision treatments, shifts in treatment methodologies, and advancements in therapies based on biomarkers.
What Are The Core Factors Supporting Growth In The Biliary Tract Cancer Market?
The expansion of the biliary tract cancer market is anticipated to be fuelled by the rise in obesity prevalence. Obesity, a persistent medical disorder typified by an overgrowth of body fat, poses significant health risks. The upsurge in the prevalence of obesity can be attributed to various factors such as inactive lifestyles, mental issues, aging, and hereditary and biological elements. Obesity can instigate chronic inflammation, insulin insensitivity, and hyper-secretion of bile acid, leading to DNA impairment and tumor proliferation. Furthermore, it can also interfere with hormones and metabolism, consequently creating a carcinogenic environment within the biliary tract. For instance, the Centers for Disease Control and Prevention, a governmental agency based in the US, reported in September 2023 that in 2022, the count of states with an adult obesity rate higher than 35% had escalated to 22 from 19, the previous year. Hence, the increasing obesity prevalence is propelling the growth of the biliary tract cancer market.
What Are The Key Segments Within The Global Biliary Tract Cancer Market?
The biliary tract cancer market covered in this report is segmented –
1) By Cancer Type: Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
2) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy
3) By End-User: Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Other End-Users
Subsegments:
1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer, Hilar Intrahepatic Bile Duct Cancer
2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer, Distal Bile Duct Cancer
3) By Gallbladder Cancer: Localized Gallbladder Cancer, Advanced Gallbladder Cancer
Pre-Book The Biliary Tract Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Biliary Tract Cancer Market?
Leading corporations in the biliary tract cancer market are shifting focus towards creating innovative combination treatments to boost effectiveness and optimize patients' results. The term 'combination therapy' refers to the concurrent use of multiple drugs or treatment approaches to manage a single condition. For instance, U.S pharmaceutical firm Merck & Co. Inc. secured approval from the U.S Food and Drug Administration (FDA) in November 2023 for its combination treatment of KEYTRUDA (pembrolizumab) with gemcitabine and cisplatin for treating patients with locally advanced, unresectable, or metastasized biliary tract cancer (BTC). This approval came on the heels of the Phase 3 KEYNOTE-966 trial, which recorded significant leaps in overall survival, cutting down death risk by 17% when compared to chemotherapy only. Patients who received the combination treatment had a median overall survival rate of 12.7 months - an increase from the 10.9 months recorded for patients who relied solely on chemotherapy. This is a noteworthy progress in therapy options for this particularly tough cancer variant.
Who Are the Key Players In The Biliary Tract Cancer Market?
Major companies operating in the biliary tract cancer market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Eli Lily and Company
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Servier Pharmaceuticals
• Jazz Pharmaceuticals plc. Incyte Corporation
• BeiGene LTD.
• Zymeworks
• Basilea Pharmaceutica Ltd.
• Taiho Oncology Inc.
• RenovoRx Inc.
• TransThera Sciences Inc.
• QED Therapeutics Inc.
• Helsinn Group
What Are The Regional Insights Into The Biliary Tract Cancer Market?
North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
